Please assess the completion status of the following clinical trial:

Trial Title: Allopurinol to Prevent Cirrhosis Related Morbidities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ge 18 to 75 years old Both sex Adults with cirrhosis in a stable conditions~Exclusion Criteria:~* Active SBP Renal insufficiency (serum creatinine \> 2.0 mg/dl) Active GIT hemorrhage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Group1: (Placebo, n=50) who will receive oral placebo tablet once daily FOR 6 MONTHS
- allopurinol (Type: ACTIVE_COMPARATOR): Group 2:(Allopurinol n=50) who will receive oral allopurinol 300 mg daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).